FILING ANALYSIS · WEDNESDAY, NOVEMBER 18
Voyager Therapeutics, Inc. VYGR — 8-K/A: Results of Operations and Financial Condition
neutral
Voyager Therapeutics reported third quarter 2026 financial results with a cash position of $132 million, extending its cash runway into Q2 2028, and announced upcoming clinical milestones, including the expected dosing of VY1706 in the next few months and tau PET imaging efficacy data from the VY7523 trial in Q4 2026.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →